Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESPR NASDAQ:QTTB NASDAQ:SPRY NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESPREsperion Therapeutics$3.16$2.92$1.00▼$4.18$814.30M1.079.09 million shs5.39 million shsQTTBQ32 Bio$12.60-1.1%$9.14$1.35▼$15.02$213.70M0.27493,236 shs192,953 shsSPRYARS Pharmaceuticals$7.94-0.9%$8.71$6.66▼$18.63$788.44M0.941.64 million shs1.15 million shsZVRAZevra Therapeutics$13.81-3.7%$11.48$7.16▼$14.58$816.45M0.911.33 million shs1.11 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESPREsperion Therapeutics+0.32%0.00%+0.96%+21.07%+221.01%QTTBQ32 Bio-9.90%+7.24%+15.29%+108.51%+755.03%SPRYARS Pharmaceuticals-6.43%-22.08%-11.69%-1.23%-54.10%ZVRAZevra Therapeutics+2.36%+10.31%+23.73%+52.39%+62.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESPREsperion Therapeutics$3.16$2.92$1.00▼$4.18$814.30M1.079.09 million shs5.39 million shsQTTBQ32 Bio$12.60-1.1%$9.14$1.35▼$15.02$213.70M0.27493,236 shs192,953 shsSPRYARS Pharmaceuticals$7.94-0.9%$8.71$6.66▼$18.63$788.44M0.941.64 million shs1.15 million shsZVRAZevra Therapeutics$13.81-3.7%$11.48$7.16▼$14.58$816.45M0.911.33 million shs1.11 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESPREsperion Therapeutics+0.32%0.00%+0.96%+21.07%+221.01%QTTBQ32 Bio-9.90%+7.24%+15.29%+108.51%+755.03%SPRYARS Pharmaceuticals-6.43%-22.08%-11.69%-1.23%-54.10%ZVRAZevra Therapeutics+2.36%+10.31%+23.73%+52.39%+62.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESPREsperion Therapeutics 2.00Hold$5.5475.04% UpsideQTTBQ32 Bio 2.60Moderate Buy$13.508.13% UpsideSPRYARS Pharmaceuticals 2.50Moderate Buy$28.20254.40% UpsideZVRAZevra Therapeutics 2.82Moderate Buy$29.29112.11% UpsideCurrent Analyst Ratings BreakdownLatest QTTB, SPRY, ZVRA, and ESPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2026SPRYARS Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $24.006/24/2026ZVRAZevra Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/23/2026ZVRAZevra Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$26.006/10/2026ZVRAZevra Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $29.006/10/2026ZVRAZevra Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $35.006/9/2026ZVRAZevra Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $29.006/9/2026ZVRAZevra Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/9/2026ZVRAZevra Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/9/2026ZVRAZevra Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.00 ➝ $27.006/9/2026ZVRAZevra Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$18.00 ➝ $25.006/8/2026ZVRAZevra Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$24.00 ➝ $34.00(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESPREsperion Therapeutics$403.14M2.02N/AN/A($1.26) per share-2.51QTTBQ32 Bio$53.74M3.94$1.34 per share9.33$3.41 per share3.66SPRYARS Pharmaceuticals$84.28M9.38N/AN/A$1.16 per share6.86ZVRAZevra Therapeutics$106.47M7.67$0.93 per share14.81$2.75 per share5.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESPREsperion Therapeutics-$22.68M-$0.06N/A14.39N/A0.12%-0.14%0.12%8/4/2026 (Estimated)QTTBQ32 Bio$29.82M$2.664.69N/AN/AN/A149.23%34.50%8/5/2026 (Estimated)SPRYARS Pharmaceuticals-$171.30M-$2.01N/AN/AN/A-200.00%-153.61%-60.85%8/12/2026 (Estimated)ZVRAZevra Therapeutics$83.23M$1.996.9414.53N/A101.58%51.49%28.86%8/11/2026 (Estimated)Latest QTTB, SPRY, ZVRA, and ESPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026SPRYARS Pharmaceuticals-$0.53-$0.61-$0.08-$0.61$22.20 million$22.68 million5/8/2026Q1 2026ESPREsperion Therapeutics-$0.02-$0.10-$0.08-$0.10$84.52 million$80.10 million5/6/2026Q1 2026ZVRAZevra Therapeutics$0.06$0.18+$0.12$0.60$31.96 million$36.22 million5/5/2026Q1 2026QTTBQ32 Bio-$0.68-$0.54+$0.14-$0.54$39.74 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthESPREsperion TherapeuticsN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESPREsperion TherapeuticsN/A1.531.18QTTBQ32 Bio0.045.365.36SPRYARS Pharmaceuticals2.794.944.77ZVRAZevra TherapeuticsN/A4.894.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESPREsperion Therapeutics47.39%QTTBQ32 Bio31.32%SPRYARS Pharmaceuticals68.16%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipESPREsperion Therapeutics1.60%QTTBQ32 Bio34.46%SPRYARS Pharmaceuticals33.80%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESPREsperion Therapeutics200257.69 million253.57 millionOptionableQTTBQ32 Bio3916.96 million11.11 millionN/ASPRYARS Pharmaceuticals9099.30 million65.74 millionOptionableZVRAZevra Therapeutics2059.12 million57.70 millionOptionableQTTB, SPRY, ZVRA, and ESPR HeadlinesRecent News About These CompaniesZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 30 at 2:26 AM | americanbankingnews.comZevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)June 23, 2026 | globenewswire.comZevra Therapeutics: Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned TransitionJune 11, 2026 | finanznachrichten.deZevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned TransitionJune 11, 2026 | markets.businessinsider.comZevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned TransitionJune 11, 2026 | globenewswire.comIs Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat?June 9, 2026 | finance.yahoo.comZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today?June 9, 2026 | finance.yahoo.comZevra Therapeutics extends MIPLYFFA exclusivity to 2041June 8, 2026 | finance.yahoo.comZVRA stock ‘way undervalued’? Analyst sees 117% upside after patent extends exclusivity till 2041 for sole approved drugJune 8, 2026 | msn.comZevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFAJune 8, 2026 | globenewswire.comZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 29, 2026 | globenewswire.comZevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They AppearMay 13, 2026 | finance.yahoo.comZevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor ConferenceMay 12, 2026 | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Zevra Therapeutics (ZVRA), Medicus Pharma Ltd (MDCX)May 11, 2026 | theglobeandmail.comZevra Therapeutics Earnings Call Highlights Growth PivotMay 10, 2026 | tipranks.comZevra Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextMay 9, 2026 | finance.yahoo.comZevra Therapeutics: Q1 Earnings SnapshotMay 7, 2026 | chron.comZevra (ZVRA) Q1 2026 Earnings Call TranscriptMay 7, 2026 | fool.comIs It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge?May 7, 2026 | finance.yahoo.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2026 Earnings Call TranscriptMay 7, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQTTB, SPRY, ZVRA, and ESPR Company DescriptionsEsperion Therapeutics NASDAQ:ESPR$3.16 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$3.16 +0.00 (+0.03%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Q32 Bio NASDAQ:QTTB$12.60 -0.14 (-1.10%) Closing price 04:00 PM EasternExtended Trading$12.54 -0.06 (-0.52%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.ARS Pharmaceuticals NASDAQ:SPRY$7.94 -0.07 (-0.87%) Closing price 04:00 PM EasternExtended Trading$8.10 +0.16 (+2.02%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.Zevra Therapeutics NASDAQ:ZVRA$13.81 -0.53 (-3.70%) Closing price 04:00 PM EasternExtended Trading$14.25 +0.44 (+3.22%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks AirJoule Unveils Prime System, Clearing Path to Commercialization Comcast’s NBCUniversal Split Puts Broadband Back in Focus Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets Ouster Is Breaking Out as a Physical AI Leader: Here's What's Driving the Move Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
